32,013 Shares in Avantor, Inc. (NYSE:AVTR) Acquired by Qsemble Capital Management LP

Qsemble Capital Management LP purchased a new position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 32,013 shares of the company's stock, valued at approximately $828,000.

A number of other large investors have also recently bought and sold shares of AVTR. Versant Capital Management Inc raised its holdings in shares of Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company's stock valued at $25,000 after buying an additional 1,102 shares during the last quarter. Blue Trust Inc. raised its stake in Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company's stock valued at $31,000 after acquiring an additional 1,391 shares during the last quarter. UMB Bank n.a. acquired a new stake in Avantor during the 3rd quarter worth approximately $49,000. Nisa Investment Advisors LLC grew its stake in shares of Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after purchasing an additional 835 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock valued at $70,000 after purchasing an additional 1,285 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Insider Buying and Selling at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now owns 29,544 shares in the company, valued at approximately $740,372.64. This trade represents a 10.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AVTR. Robert W. Baird decreased their price target on Avantor from $27.00 to $26.00 and set an "outperform" rating for the company in a report on Monday, October 28th. UBS Group reduced their target price on shares of Avantor from $30.00 to $29.00 and set a "buy" rating for the company in a research note on Tuesday, October 8th. Royal Bank of Canada reiterated an "outperform" rating and set a $34.00 price target on shares of Avantor in a research note on Thursday, September 26th. Wells Fargo & Company reduced their price objective on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Monday, October 28th. Finally, Barclays dropped their target price on Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a research report on Friday, October 25th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $27.57.

Avantor Price Performance

NYSE AVTR traded up $0.09 during trading hours on Wednesday, reaching $21.10. The company's stock had a trading volume of 426,653 shares, compared to its average volume of 6,483,064. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The company's 50-day moving average is $23.65 and its two-hundred day moving average is $23.79. Avantor, Inc. has a fifty-two week low of $19.59 and a fifty-two week high of $28.00. The stock has a market cap of $14.36 billion, a PE ratio of 45.67, a PEG ratio of 2.56 and a beta of 1.35.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.